Invested in Her moves its deadline to October as the LSF seeks $250,000 for early-stage research into menopause and ovarian aging.
The Longevity Science Foundation (LSF) has pushed back the deadline for its Invested in Her campaign to 1 October, buying itself another month to reach its $250,000 target for research into ovarian aging, menopause and the long reach both have into female healthspan. Clear the goal by then, and a further $25,000 arrives courtesy of LongeVC – a modest incentive, perhaps, but a useful one; crowdfunding campaigns rarely come with a matching bonus attached.
So far, the campaign has raised over $64,000, a sum that, while not inconsiderable, still leaves plenty of room for new backers to help close the gap. The money is earmarked for three linked pursuits: better measurement of reproductive aging, a clearer biological account of how ovarian decline feeds into systemic aging, and early interventions that might modify the process rather than simply chronicle it. The extension follows an Invested in Her event at 7 World Trade Center in New York this August, where researchers, clinicians, investors, founders and philanthropists gathered to ask a question the field has left unanswered for rather too long: who, exactly, is meant to pay for women’s health research in the first place.
Longevity.Technology: The $64,667 raised so far may be some distance from the campaign’s $250,000 target, but perhaps the more interesting number is not the one on the fundraising thermometer. If longevity medicine is serious about moving healthcare upstream – intervening earlier, preserving function and preventing disease rather than waiting to treat its consequences – then someone has to fund the science before it is sufficiently validated, de-risked and packaged to become an attractive investment proposition.
Ovarian aging is a particularly neat illustration of that uncomfortable funding gap; the biology has implications stretching well beyond fertility, but promising early-stage research can still find itself stranded between scientific rationale and commercial readiness. Crowdfunding is unlikely to replace grants, philanthropy or venture capital – nor should we expect it to – but it can provide something disproportionately valuable: evidence that people think a question is worth answering.
The real return on this campaign, therefore, may ultimately be leverage rather than dollars. If relatively modest public backing helps unlock substantially larger pools of research funding and investment, the crowd does not need to finance the whole journey; sometimes, it just needs to make enough noise that those holding the bigger checkbooks pay attention.
Funding the full picture
Rather than directing funds toward a single therapeutic hypothesis, the LSF has organized its proposed research portfolio around measurement, biology and intervention. The first includes work on molecular sensors and a proposed “menopause clock” designed to track reproductive biomarkers, potentially moving assessment beyond symptoms and menstrual history toward more precise biological measurement.
The second focuses further upstream, examining mechanisms that could connect reproductive aging with changes in cognition, metabolism and whole-body aging; proposed areas include cellular senescence, estrogen-related effects on brain circuitry and molecular and epigenetic mechanisms involved in ovarian aging.
Intervention is the most translational – and, inevitably, the furthest from routine clinical application. Projects identified by the LSF include gene therapy approaches intended to slow ovarian aging, as well as partial epigenetic reprogramming aimed at restoring more youthful molecular signatures in ovarian tissue. While these are early-stage research directions, and not established treatments, they nevertheless reflect a changing scientific premise in which reproductive aging is increasingly being investigated as potentially modifiable biology rather than an immutable timetable.
From interest to constituency
That shift in thinking was also visible in New York. The August event combined presentations and panel discussions with conversations spanning venture capital, brain health and the persistent difficulties of funding women’s health; when attendees were asked to identify the biggest barriers to progress, healthcare system design and lack of research funding led the responses.
An event cannot, of course, validate a scientific hypothesis – nor can enthusiasm substitute for data. What it can do is show that ovarian aging is beginning to attract a broader constituency around the laboratory work. For a research area historically caught between reproductive medicine, endocrinology and geroscience, that widening circle may matter.
A longer runway
The extra month gives Invested in Her more time to convert that attention into capital; whether it can close the considerable distance still remaining to $250,000 will become clear by October. More interesting, perhaps, will be what follows – whether early public backing can give promising ovarian aging research enough runway to generate the evidence that brings larger funders aboard.
To find out more about Invested in Her or to contribute to the campaign, visit the Longevity Science Foundation website.
Photographs courtesy of Longevity Science Foundation
